
|Articles|November 15, 2002
Once-daily glaucoma therapy better tolerated than b.i.d.
Houston-In patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH), once-daily treatment with fixed-combination latanoprost/timolol (Xalacom, Pharmacia, Peapack, NJ) is well tolerated and lowers IOP more effectively than twice-daily dorzolamide/timolol (Cosopt, Merck), according to a recent multicenter U.S. study.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote
2
Preclinical study suggests synaptic regeneration may offer new pathway to treat glaucoma
3
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
4
AAO 2025: Arshad M. Khanani, MD, highlights 3-year results from the GATHER2 open-label extension trial
5